Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674649 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL3671539 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL11024470 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL3677438 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL3680384 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL3673657 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL3682609 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL5902919 | 0.87 | PTGER4 (0.39) | PTGER4PTGER3PTGER2 | |
| SCHEMBL16089510 | 0.87 | PTGER4 (0.54) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL5902684 | 0.87 | PTGER4 (0.41) | PTGER4PTGER3PTGER2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015109112-A1 | COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS | GEMMUS PHARMA INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2015109112-A1 | COMBINATION TREATMENT OF ANTIBIOTIC AND GPCR AGONIST FOR VIRAL/BACTERIAL CO-INFECTIONS | GEMMUS PHARMA INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | GEMMUS PHARMA, INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196578-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGER4 1/4885PTGER3 15/4885PTGER2 27/4885 |
| US-20120190637-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | PTGER4, TMPRSS4, GPR4 | PTGER4 1/4885PTGER3 15/4885PTGER2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.